BeiGene、BeOne Medicinesへリブランド、スイスへ本社移転
This strategic shift signifies BeiGene's evolution into a global entity, BeOne Medicines, with a new corporate structure and domicile.
Company name change and redomiciliation to Switzerland.
百济神州美国子公司已于2025年3月17日正式更名为BeOne Medicines USA, Inc.。此次更名以及计划迁往瑞士的举措尚待股东批准。公司表示，新名称体现了其致力于开发创新药物并与全球合作以帮助癌症患者的承诺。
This strategic shift signifies BeiGene's evolution into a global entity, BeOne Medicines, with a new corporate structure and domicile. The move to Switzerland, a hub for life sciences, could streamline international operations and access to capital. While the primary focus is global, this restructuring impacts its APAC operations by aligning them under a new international framework and potentially influencing future investment and strategic partnerships within the region.
The rebranding and redomiciliation to Switzerland create a new global corporate identity for BeiGene. This impacts its APAC operations by integrating them into a unified international strategy, potentially influencing regional investment, partnerships, and market access initiatives under the BeOne Medicines umbrella.
Where this signal fits in the broader landscape.
BeiGene、2025年第4四半期および通期決算を発表
BeOne Medicines、2025年第4四半期および通期決算を発表
ビーゲン社のPD-1阻害薬ティスレリズマブ、日本で承認取得 グローバル製薬大手に挑む
BeOne Medicines、2025年第4四半期および通期決算を発表へ
BeiGene社、ソノロトクラックスが再発・難治性マントル細胞リンパ腫（R/R MCL）で世界初の承認を取得
https://www.linkedin.com/company/beigene/
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン